Heparinized Islets in Clinical Islet Transplantation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT00678990
Recruitment Status : Not yet recruiting
First Posted : May 16, 2008
Last Update Posted : August 22, 2017
Information provided by (Responsible Party):
Corline Biomedical AB

Brief Summary:
In this study the islets will be surface modified to carry immobilised heparin (Corline Heparin Conjugate) prior to transplantation. The primary objective is to investigate safety and efficacy of allogeneic islet transplantation using islets coated with immobilised heparin. The modification with heparin has been shown to protect the islets from being attacked by the immediate defence systems in blood (coagulation and inflammation), so that a larger portion of the islets will survive the initial phase and engraft. Evaluation will be based on metabolic and blood chemistry parameters.

Condition or disease Intervention/treatment Phase
Type 1 Diabetes Mellitus Procedure: Transplantation of islets with heparin coating Not Applicable

Detailed Description:

Transplantation of islets of Langerhans isolated from donated organs is a promising therapy for diabetes type 1. The results so far have, however, not met with the expectations due to relatively low efficiency. Even in situations where the patients have become insulin-free, it has been estimated that the transplanted islet mass is less than 25% of the islet mass of a healthy individual, which in many cases has required repeated use of insulin injections. The islets are transferred to the patient by an infusion drop to the liver via the portal vein.

Researches within the Nordic Network for Clinical Islet Transplantation have in a series of publications shown that the islets are subject to a violent immunological reaction that is non-specific with regard to the individual patient (IBMIR) during the initial contact with blood (Moberg et al, Lancet 2002, among several). The IBMIR reaction is in the earliest phase mediated by coagulation and complement reactions.

In this study the islets will be surface modified to carry immobilised heparin (Corline Heparin Conjugate) prior to transplantation. The primary objective is to protect the islets from being attacked by IBMIR so that a larger portion of the islets will survive the initial phase and engraft. In a paper published by the research group (Cabric et. al., Diabetes, May 2007), the beneficial effects of immobilised heparin on the islets to counteract IBMIR were shown by experiments at the lab bench and in experimental animals.

The evaluation of the transplantations in this study will be based on metabolic and blood chemistry parameters, similar to the evaluations of other transplanted patients within the Nordic Network.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open Study to Evaluate Safety and Efficacy of Allogenic Islet Transplantation Using Islets Coated With Immobilised Heparin
Estimated Study Start Date : January 2018
Estimated Primary Completion Date : December 2018
Estimated Study Completion Date : December 2018

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Open, single arm
Transplantation of islets with heparin coating.
Procedure: Transplantation of islets with heparin coating
Transplantation of islets with heparin coating

Primary Outcome Measures :
  1. Safety [ Time Frame: 105 days ]
    Number of and grade of Serious Adverse events during the first 105 days after transplantation and Adverse events during the first 75 days after transplantation.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

  1. Male and female patients age 18 to 65 years of age.
  2. Ability to understand and provide written informed consent.
  3. Mentally stable and able to comply with the procedures of the study protocol.
  4. Clinical history compatible with type 1 diabetes with onset of disease at < 40 years of age and insulin-dependence for > 5 years at the time of enrolment.
  5. Stimulated C-peptide < 0.3 ng/mL (0.1 nmol/L) in response to a MMTT, before first islet transplantation.
  6. All subjects must have received medical treatment of their diabetes under the guidance from an experienced endocrinologist.

    If not previously transplanted the patient must also have;

  7. At least one episode of severe hypoglycaemia in the past 1 year defined as an event with at least one of the following symptoms; memory loss, confusion, uncontrollable behaviour, unusual difficulty in awakening, suspected seizure, loss of consciousness, or visual symptoms, in which the subject was unable to treat him/herself and which was associated with either a blood/plasma glucose level < 54 mg/dl (3.0 mmol/L) or prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration OR
  8. Reduced awareness of hypoglycaemia as defined by a Clarke score of 4 or more.

Exclusion Criteria

Patients who meet any of these criteria are not eligible for participation in the study:

  1. Patients with prior organ transplants other than a kidney graft and/or islets.
  2. Patients with body mass index (BMI) > 30.
  3. Insulin requirement > 1 Unit/kg/day at screening.
  4. Consistently abnormal liver function tests (> 1.5 x ULN on two consecutive measurements > 2 weeks apart), at screening.
  5. Proliferative untreated diabetic retinopathy
  6. Increased risk for thrombosis (ex. homozygous APC-resistance) or bleeding (INR>1.5)
  7. Any history of malignancy except for completely resected squamous or basal cell carcinoma of the skin
  8. Patients with increased cardiac risk defined as;

    1. unstable coronary artery disease requiring hospitalization or revascularization within 6 months prior to baseline visit
    2. chronic heart failure which required hospitalization 30 days prior to baseline visit
  9. Patients with active infections, unless treatment is not judged necessary by the investigators
  10. Patients with serological evidence of infection with HIV, hepatitis B (patients with serology consistent with previous vaccination and a history of vaccination are acceptable) or hepatitis C.
  11. Patients with active peptic ulcer disease, symptomatic gallstones or portal hypertension.
  12. Patients who are pregnant or breastfeeding, or who intend to become pregnant.
  13. Sexually active females who are not:

    1. post-menopausal,
    2. surgically sterile, or
    3. using a highly effective method of contraception, such as: intra uterine device, oral contraceptives, implants, injectables or barrier devices combined with spermicidal gel
  14. Active alcohol or substance abuse
  15. Patients with evidence of high-level sensitization (PRA> 50% with flow cytometry).
  16. Patients with psychological conditions that make it unsafe to undergo islet transplantation or which preclude compliance with prescribed therapy
  17. HbA1c >11% (International standard) corresponding to IFCC calibration 97 mmol/mol, at screening.
  18. Medical history of egg allergy
  19. Patients with any condition or any circumstance that in the opinion of the investigator would make it unsafe to undergo an islet transplant
  20. Patients participating in or having participated in any other clinical drug studies in the past four weeks.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00678990

Contact: Tomas Lorant +46 18 6110000

Department of Transplantation Surgery, Karolinska University Hospital Not yet recruiting
Stockholm, Sweden, SE-141 86
Contact: Torbjörn Lundgren, MD    +46 73 6994946   
Principal Investigator: Torbjörn Lundgren, MD         
Department of Transplantation and Liver Surgery, Uppsala University Hospital Not yet recruiting
Uppsala, Sweden, SE-751 85
Contact: Tomas Lorant, MD    +46 18 6110000   
Principal Investigator: Tomas Lorant, MD         
Sponsors and Collaborators
Corline Biomedical AB
Principal Investigator: Tomas Lorant Uppsala University Hospital

Responsible Party: Corline Biomedical AB Identifier: NCT00678990     History of Changes
Other Study ID Numbers: SAL-01
First Posted: May 16, 2008    Key Record Dates
Last Update Posted: August 22, 2017
Last Verified: August 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Corline Biomedical AB:
Islets of Langerhans

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
Calcium heparin
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action